Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Top Value Stocks
- RTI: When Will We Finally See a Pullback?
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Insurance Industry Stock Outlook - May 2013
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- Biotechnology ETF Investing 101
- AWS 5/21: The Beginning of the End for QE
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. ( BIIB - Analyst Report ) in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. Angiomax is the company’s lead product, accounting for 99.8% of total revenues in 2010.
Teva admitted that the two patents challenged by it are valid and enforceable and would be infringed by its generic version. The patents, which were the focus of the patent infringement lawsuit, are slated to expire on July 27, 2028.
ANDAs Filed in 2009
Teva and its affiliate, Pliva Hrvatska d.o.o., had filed abbreviated new drug applications (ANDA) in 2009 seeking US Food and Drug Administration (FDA) approval for their generic versions of Angiomax. Later that year, The Medicines Company filed patent infringement lawsuits against the generic companies.
Details of the Settlement Agreement
Per the terms of the settlement agreement, The Medicines Company granted a license to Teva and its affiliates under which they can launch a generic version of Angiomax in the US on June 30, 2019. The generic could be launched earlier under certain specific circumstances.
The Medicines Company also signed an agreement with Teva under which the latter will supply Angiomax’ active pharmaceutical ingredient (API) to The Medicines Company.
The settlement of the patent infringement lawsuit removes a significant overhang from The Medicines Company. With Angiomax accounting for a major part of the company’s revenue, the delay in the entry of generic versions of the product is a huge positive.
Although The Medicines Company is still facing patent challenges for Angiomax from other generic companies like APP Pharmaceuticals, Hospira (HSP), Mylan Pharmaceuticals (MYL) and Dr. Reddy's Laboratories (RDY), we believe the company will enter into settlement agreements with these companies as well to delay the entry of generics.
We currently have a Neutral recommendation on The Medicines Company, which carries a Zacks #3 Rank (short-term Hold rating).
Read the full Analyst Report on MDCO
Read the full Analyst Report on TEVA
Read the full Analyst Report on BIIB